Distribution of vasoactive intestinal peptide( VIP)- and substance P (SP)- containing innervation in bronchi of patients with bronchial asthma Source: Eur Respir J 2004; 24: Suppl. 48, 128s Year: 2004
Serum level of VIP (vasoactive intestinal polypeptide) in patients with COPD in stable state and during exacerbation Source: Eur Respir J 2001; 18: Suppl. 33, 483s Year: 2001
Vasoactive intestinal peptide receptor 2 (VIPR2) in central airways of smokers Source: Eur Respir J 2002; 20: Suppl. 38, 88s Year: 2002
Vasoactive intestinal peptide receptors in the airways of smokers with chronic bronchitis Source: Eur Respir J 2004; 24: 958-963 Year: 2004
Vitamin C, VIP (vasoactive intestinal polypeptide) and gastrin in the serum of COPD patients in stable state and during exacerbation Source: Eur Respir J 2002; 20: Suppl. 38, 259s Year: 2002
VIP (vasoactive intestinal polypeptide) and vitamin C in the serum of COPD patients before and after therapy Source: Eur Respir J 2006; 28: Suppl. 50, 37s Year: 2006
Inhaled substance P, but not neurokinin A, enhances levels of alpha-2-macroglobulin in induced sputum of patients with mild asthma Source: Eur Respir J 2001; 18: Suppl. 33, 162s Year: 2001
Vasoactive intestinal peptide (VIP) for treatment of COPD: improvement in spiroergometry and 6 minute walking distance Source: Eur Respir J 2006; 28: Suppl. 50, 430s Year: 2006
Gastro-oesophageal reflux (GER) and airway responsiveness to methacholine, physical exercise and capsaicin in bronchial asthma: effect of gastric acid secretion inhibition Source: Eur Respir J 2002; 20: Suppl. 38, 50s Year: 2002
Effect of inhaled fluticasone on bronchial responsiveness to neurokinin A in asthma Source: Eur Respir J 2002; 19: 997-1002 Year: 2002
Inhaled vasoactive intestinal peptide (VIP) improves pulmonary gas exchange in acute respiratory distress syndrome (ARDS) - a case report Source: Eur Respir J 2003; 22: Suppl. 45, 70s Year: 2003
Inhalation of vasoactive intestinal peptide in pulmonary hypertension Source: Annual Congress 2008 - Medical treatment of pulmonary hypertension Year: 2008
The role of topical nasal steroids (TNS) in the treatment of bronchial asthma (BA) combined with nasal polyposis (NP) Source: Eur Respir J 2004; 24: Suppl. 48, 259s Year: 2004
Differences in nasal fluid levels of myeloperoxidase (MPO) and fucose after lavage with saline and histamine solutions, respectively, may indicate a neutrophil inflammation in the nasal mucosa in patients with COPD, and moreover, a glandular Source: Eur Respir J 2002; 20: Suppl. 38, 93s Year: 2002
Involvement of the airway vasculature in the late asthmatic response (LAR) to allergen Source: Eur Respir J 2006; 28: Suppl. 50, 672s Year: 2006
Functional activity of bronchial neutrophils in the patients with cold airway hyperresponsiveness (CAHR) in severe asthma Source: International Congress 2017 – Translational studies of lung disease Year: 2017
Low triiodothyronine (T3 ) state and bronchial responsiveness to cold air provocation in patients with bronchial asthma Source: Annual Congress 2009 - Airway hyperresponsiveness: mechanism and assessment Year: 2009
Vasoactive intestinal peptide (VIP) markedly attenuates pulmonary hypertension in fawn-hooded rats Source: Annual Congress 2005 - Pulmonary hypertension: pathophysiology Year: 2005
Characteristics of eosinophilic and neutrophilic inflammation of bronchi of the bronchial asthma (BA) patients Source: Eur Respir J 2001; 18: Suppl. 33, 32s Year: 2001
Vasoactive intestinal peptide-receptor regulation in monocytes derived from COPD patients Source: Annual Congress 2007 - Cell biology of asthma and COPD Year: 2007